Saturday, November 2, 2024
HomeTagsRegenerative medicine platform

regenerative medicine platform

Direct Biologics Announces FDA Authorization to Expand Ongoing Phase 3 Clinical Study of ExoFlo™ to All-Cause Moderate-to-Severe ARDS

Direct Biologics, LLC, a late-stage biotechnology company leveraging its regenerative medicine platform using extracellular vesicles (EVs) secreted from bone marrow-derived mesenchymal stem cells to...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics